Please ensure Javascript is enabled for purposes of website accessibility

Adaptive Biotechnologies and Microsoft Announce New Study of COVID-19 Immune Response

By Taylor Carmichael - May 6, 2020 at 12:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The "ImmuneRace" study will genetically map the T-cells of 1,000 people who have been exposed to SARS-CoV-19.

Adaptive Biotechnologies (ADPT 2.53%) has begun a virtual clinical study to map the immune responses of people who have contracted COVID-19 or who are likely to have. Working with Microsoft (MSFT -0.29%)Illumina (ILMN 0.83%), and LabCorp (LH 0.75%), the biotech company is collecting blood samples from people in 24 U.S. cities that have been hard hit by the disease.

Currently, there are two types of tests for COVID-19. The first are PCR (polymerase chain reaction) tests, which reveal whether a person is currently infected. These tests are based on the DNA of the coronavirus, and all researchers need is a nose or throat swab from the patient to run them.

The second type is a serology test: Using a sample of the patient's blood, this will look for the presence of specific antibodies that are generated by the immune system in response to SARS-CoV-2. Unlike a PCR test, serology tests will reveal people who have recovered from COVID-19 and no longer have active infections.

DNA graphic

Image source: Getty Images

Adaptive Bio is creating an even more specific test that will detect the presence of T cells (white blood cells that bind to and kill infected cells). Then, working with Illumina and Microsoft, the company will use machine learning to map the genomes of all the immune receptors responding to SARS-CoV-2. 

This mapping is similar to what scientists did with the human genome two decades ago. Those scientists had to sequence 30,000 genes, compared to the millions of genes Adaptive is mapping.

The ImmuneRace study will be a real-world test of whether Adaptive Bio can successfully map our immune response to a new and dangerous disease. As of noon Wednesday, the company's stock was up 1.9%.

Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Taylor Carmichael owns shares of Adaptive Biotechnologies. The Motley Fool owns shares of and recommends Illumina and Microsoft and recommends the following options: long January 2021 $85 calls on Microsoft and short January 2021 $115 calls on Microsoft. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adaptive Biotechnologies Corporation Stock Quote
Adaptive Biotechnologies Corporation
ADPT
$11.74 (2.53%) $0.29
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$282.08 (-0.29%) $0.83
Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$225.63 (0.83%) $1.86
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
LH
$256.59 (0.75%) $1.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.